文献速递类风湿关节炎

托法替布与托珠单抗治疗甲氨蝶呤难治性活动性类风湿关节炎的比较

Tofacitinib versus tocilizumab in the treatment of biological-naïve or previous biological-failure patients with methotrexate-refractory active rheumatoid arthritis.
PubMed 文献 · RMD Open · 2021-01-01

本研究基于两个真实世界注册库,比较托法替布与托珠单抗在生物制剂初治或既往生物制剂失败的活动性RA患者中的疗效。经倾向评分匹配调整后,在生物制剂初治患者中托法替布在12个月时达到CDAI85、CDAI70和缓解的可能性高于托珠单抗,但该差异在既往生物制剂失败患者中未观察到。

要点

  • 生物制剂初治RA患者中,托法替布12个月CDAI85的OR为3.88(95%CI 1.87-8.03)。
  • 生物制剂初治RA患者中,托法替布12个月缓解的OR为3.31(95%CI 1.69-6.48)。
  • 既往生物制剂失败患者中未观察到托法替布与托珠单抗的疗效差异。

核心结论

  • 与托珠单抗相比,托法替布在生物制剂初治患者治疗前12个月可诱导更大改善,但该差异在既往生物制剂失败患者中未观察到。

研究设计与样本

  • 研究使用两个正在进行的真实世界注册库,纳入2013年8月至2019年2月期间首次开始托法替布或托珠单抗治疗的RA患者。
  • 共纳入464例中高CDAI的RA患者,其中托法替布247例,托珠单抗217例;采用倾向评分匹配调整治疗选择偏倚。

主要发现

  • 在生物制剂初治患者中,托法替布比托珠单抗更可能诱导和维持12个月CDAI85、CDAI70和缓解。
  • 调整MTX和泼尼松龙合并使用后,托法替布对比托珠单抗的OR为:CDAI85 3.88(95%CI 1.87-8.03)、CDAI70 2.89(95%CI 1.43-5.84)、缓解3.31(95%CI 1.69-6.48)。
  • 在既往生物制剂失败患者中未观察到上述效应。
  • 在托法替布治疗的既往生物制剂失败患者中,既往失败bDMARD类别数与CDAI改善无关。
  • 两种治疗的总不良事件率相似;采用逆概率治疗加权调整后获得相似OR。

关键数值与推荐

  • 生物制剂初治患者中,托法替布对比托珠单抗12个月CDAI85的OR为3.88(95%CI 1.87-8.03)。
  • 生物制剂初治患者中,托法替布对比托珠单抗12个月CDAI70的OR为2.89(95%CI 1.43-5.84)。
  • 生物制剂初治患者中,托法替布对比托珠单抗12个月缓解的OR为3.31(95%CI 1.69-6.48)。

临床怎么用

  • 对于甲氨蝶呤难治性活动性RA且未使用过生物制剂的患者,托法替布可能较托珠单抗在12个月时带来更高的CDAI85、CDAI70和缓解率。
  • 对于既往生物制剂失败的RA患者,托法替布与托珠单抗的疗效差异未观察到,选择时需综合考虑。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare effectiveness between tofacitinib and tocilizumab treatments for biological disease-modifying antirheumatic drug (bDMARD)-naïve patients or previous bDMARD-failure patients with active rheumatoid arthritis (RA) refractory to methotrexate (MTX). METHODS: We used two ongoing real-world registries of patients with RA who had first started tofacitinib or tocilizumab between August 2013 and February 2019 at our institutions. Clinical disease activity index (CDAI)-based improvements at 12 months were used for comparisons between tofacitinib and tocilizumab treatments, separately for bDMARD-naïve and previous bDMARD-failure patients. RESULTS: A total of 464 patients with RA with high or moderate CDAI were enrolled (247 with tofacitinib and 217 with tocilizumab). After adjustments for treatment-selection bias by propensity score matching, we showed that tofacitinib was more likely to induce and maintain ≥85% improvement in CDAI (CDAI85), CDAI70 and remission at 12 months compared with tocilizumab in bDMARD-naïve patients. After adjusting for concurrent use of MTX and prednisolone, the ORs of tofacitinib versus tocilizumab were 3.88 (95% CI 1.87 to 8.03) for CDAI85, 2.89 (95% CI 1.43 to 5.84) for CDAI70 and 3.31 (95% CI 1.69 to 6.48) for remission. These effects were not observed in bDMARD-failure patients. In tofacitinib treatment for bDMARD-failure patients, the number of previously failed bDMARD classes was not associated with CDAI-based improvements. The rate of overall adverse events was similar between both treatments. Similar ORs were obtained from patients adjusted by inverse probability of treatment weighting. CONCLUSIONS: Compared with tocilizumab, tofacitinib can induce greater improvements during the first 12-month treatment in bDMARD-naïve patients, but this difference was not observed in previous bDMARD-failure patients.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Mori S, Urata Y, Yoshitama T, et al. Tofacitinib versus tocilizumab in the treatment of biological-naïve or previous biological-failure patients with methotrexate-refractory active rheumatoid arthritis. RMD Open. 2021. PMID: 33958440. doi:10.1136/rmdopen-2021-001601

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。